Drug Trial Radar · NCT03778931
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
478
Actual
Start
May 10, 2019
Primary completion
Aug 24, 2021
Study completion Aug 22, 2024
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).
Conditions
- Breast Cancer
Interventions
ElacestrantDrug
400 mg/day once daily oral dosing
Standard of CareDrug
* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle * Anastrozole 1 mg/day on a continuous dosing schedule * Letrozole: 2.5 mg/day on a continuous dosing schedule * Exemestane: 25 mg/day on a continuous dosing schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival in ESR1-mut ParticipantsTime frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
- Progression-free Survival in All ParticipantsTime frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
Locations
244 sites in 17 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
St Bernard's Cancer Care
Jonesboro, Arkansas
St. Jude Heritage Healthcare
Fullerton, California
Adventist Health Glendale
Glendale, California
Moores Cancer Center at UC San Diego Health
La Jolla, California
Keck Hospital of USC-Norris Healthcare (HC3), Investigational Drug Service (IDS)
Los Angeles, California
Keck Medical Center of USC
Los Angeles, California
USC IDS Pharmacy
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
UCLA West Medical Pharmacy 159
Los Angeles, California
TMPN Cancer Care
Redondo Beach, California
UC Davis Medical Center, Investigational Drug Service
Sacramento, California
UCSF Medical Center
San Francisco, California
Ridley-Tree Cancer Center
Santa Barbara, California
Anschutz Cancer Center Pavilion
Aurora, Colorado
US Oncology - Rocky Mountain Cancer Centers - Midtown
Denver, Colorado
Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System
Fort Collins, Colorado
UCHealth Cancer Center
Fort Collins, Colorado
Yale Cancer Center
New Haven, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Orlando Health Cancer Institute
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Piedmont Cancer Institute, P.C. - Oncology
Atlanta, Georgia
Suburban Hematology-Oncology Associates
Lawrenceville, Georgia
Northwest Georgia Oncology Centers
Marietta, Georgia
Chicago Association for Research and Education in Science
Chicago, Illinois
Rush University Cancer Center
Chicago, Illinois
Cancer Care Center of Decatur
Decatur, Illinois
Joliet Oncology-Hematology Associates
Joliet, Illinois
Presence Medical Group Hematology Oncology
Skokie, Illinois
Simmons Cancer Institute
Springfield, Illinois
Healthcare Research Network II
Tinley Park, Illinois
Fort Wayne Medical Oncology And Hematology
Fort Wayne, Indiana
Goshen Center for Cancer Care
Goshen, Indiana
Hematology Oncology Of Indiana
Indianapolis, Indiana
Cancer Resource Centre
Munster, Indiana
University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute
Louisville, Kentucky
Pikeville Medical Center - Oncology/Hematology
Pikeville, Kentucky
Ochsner Medical Center
New Orleans, Louisiana
Showing 40 of 244 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.